Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MNPR 
Monopar Therapeutics Inc (MNPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MNPR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $61.02
1 Year Target Price $61.02
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 258.52% | Avg. Invested days 61 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 205.47M USD | Price to earnings Ratio - | 1Y Target Price 61.02 |
Price to earnings Ratio - | 1Y Target Price 61.02 | ||
Volume (30-day avg) 5 | Beta 1.01 | 52 Weeks Range 1.72 - 54.30 | Updated Date 06/30/2025 |
52 Weeks Range 1.72 - 54.30 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.49% | Return on Equity (TTM) -54.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 200651196 | Price to Sales(TTM) - |
Enterprise Value 200651196 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6115210 | Shares Floating 2902709 |
Shares Outstanding 6115210 | Shares Floating 2902709 | ||
Percent Insiders 34.38 | Percent Institutions 47.24 |
Analyst Ratings
Rating 3 | Target Price 61.02 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Monopar Therapeutics Inc
Company Overview
History and Background
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics to treat cancer and other serious diseases. Founded in 2014, it has advanced multiple programs into clinical trials.
Core Business Areas
- Oncology Therapeutics Development: Focuses on developing treatments for various cancers, including Validive for severe oral mucositis and camsirubicin for advanced soft tissue sarcoma.
Leadership and Structure
The leadership team includes Chandler D. Robinson, MD (CEO), Andrew Mazar, PhD (CSO). The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Validive (Clonidine Topical Solution): Being developed for the treatment of severe oral mucositis caused by cancer therapies. Competitors include Helsinn Healthcare SA (Aloxi).
- Camsirubicin: A novel topoisomerase II inhibitor being developed for the treatment of advanced soft tissue sarcoma. Competitors include Eli Lilly and Company (Olaratumab).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, driven by increasing cancer incidence and advancements in treatment modalities.
Positioning
Monopar focuses on niche areas within oncology, such as oral mucositis and soft tissue sarcoma, seeking to address unmet medical needs. Competitive advantages include its proprietary drug candidates and clinical development expertise.
Total Addressable Market (TAM)
The TAM for oral mucositis treatments is estimated to be in the hundreds of millions of dollars annually. The TAM for soft tissue sarcoma treatments is in the billions annually. Monopar is positioning itself to capture a portion of these markets with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Experienced management team
- Focus on unmet medical needs
- Clinical-stage development programs
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Small market capitalization
- No currently marketed products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory approvals for key products
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Economic downturn
Competitors and Market Share
Key Competitors
- LLY
- HSIC
Competitive Landscape
Monopar is a smaller player compared to established pharmaceutical companies. Its competitive advantage lies in its focus on niche areas and proprietary drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of clinical programs.
Future Projections: Future growth is dependent on clinical trial success and potential partnerships. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing Validive and camsirubicin through clinical trials.
Summary
Monopar Therapeutics is a clinical-stage biopharmaceutical company with a focus on oncology. Its success hinges on clinical trial outcomes and securing partnerships to fund further development. The company faces stiff competition from larger, established pharmaceutical companies. Positive results could lead to significant growth, but failure to achieve clinical milestones could negatively impact the company. Its small market capitalization and dependence on clinical trial outcomes increase the risk for investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monopar Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmette, IL, United States | ||
IPO Launch date 2019-12-19 | Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.monopartx.com |
Full time employees 14 | Website https://www.monopartx.com | ||
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.